InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
82.11
(
0.28%
)
Bitcoin
68,275.75
(
1.63%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 247778

Wednesday, 06/28/2023 1:46:01 PM

Wednesday, June 28, 2023 1:46:01 PM

Post# of 252642
ESPR’s Nexletol—(bempedoic acid)—had only a modest effect size on MACE endpoints in a large outcomes study that read out in Mar 2023 (#msg-171369854).

Based on that trial, ESPR’s partner, Daiichi Sankyo is pulling out of the partnership and is refusing to pay ESPR a $300M milestone that was based on the clinical data (#msg-171455404).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up